Kinestica

Kinestica operates at the intersection of medical devices, rehabilitation technology, and robotics, with a focus on neurological recovery and physical therapy. Its portfolio addresses several therapy needs: Bimeo Pro targets upper-limb rehabilitation, Equio combines balance training with assessment, and HOMER is described as a home-based post-stroke rehabilitation system. RoR focuses on balance and safety for older adults, while REHAROBO is a passive upper-limb rehabilitation robot. The company’s stated differentiators are sensor-based movement tracking, real-time feedback, objective progress reporting, and gamified exercises. These features distinguish its product approach, but the available profile does not provide comparative clinical outcomes, pricing, adoption figures, or market share. No distinct competitor companies are identified; repeated similarity entries refer to Kinestica itself and are not treated as peers. This limits direct competitor comparison. Its public profile instead supports a view of a specialized medical-device developer serving clinical and home rehabilitation use cases, rather than a broad digital-health software provider.

Kinestica’s recorded trajectory began with Bimeo prototype development in 2009, followed by company formation in 2012 and early grant support. It received grants of $13,055 in September 2012 and $94,294 in January 2013, then a $520,583 seed round in January 2015 and a further $53,319 grant in December 2016. These four rounds total $681,251, with the 2015 seed round accounting for most of the disclosed funding. Product descriptions indicate a broader portfolio than the original Bimeo concept: Bimeo Pro addresses upper-limb therapy, Equio targets balance assessment and training, and HOMER extends rehabilitation into the home; RoR and REHAROBO cover additional balance and motor-rehabilitation needs.